Which has higher valuation & earnings, CTOR or IMRX?

Immuneering is trading at a lower price-to-earnings ratio than Citius Oncology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Citius Oncology N/A N/A -$24.76M -$0.47 N/A Immuneering N/A N/A -$56.03M -$1.17 N/A

Is CTOR or IMRX more profitable?

Immuneering's return on equity of -31.93% beat Citius Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Citius Oncology N/A -99.47% -42.16% Immuneering N/A -31.93% -29.92%

Which has stronger earnings & valuation, ELDN or CTOR?

Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Citius Oncology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eledon Pharmaceuticals N/A N/A -$45.62M -$0.77 N/A Citius Oncology N/A N/A -$24.76M -$0.47 N/A

Is ELDN or CTOR more profitable?

Citius Oncology's return on equity of -99.47% beat Eledon Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Eledon Pharmaceuticals N/A -116.97% -41.91% Citius Oncology N/A -99.47% -42.16%

Is CTOR or SRZN more profitable?

Citius Oncology has a net margin of 0.00% compared to Surrozen's net margin of -4,810.50%. Citius Oncology's return on equity of -99.47% beat Surrozen's return on equity. Company Net Margins Return on Equity Return on Assets Citius Oncology N/A -99.47% -42.16% Surrozen -4,810.50% -4,055.04% -154.08%

Citius Oncology (CTOR) Competitors

$0.66 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$0.66 0.00 (0.00%)

As of 06/12/2026 05:53 PM Eastern

Compare

CTOR vs. IMRX, ELDN, TKNO, NAGE, and SRZN

Should you buy Citius Oncology stock or one of its competitors? MarketBeat compares Citius Oncology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Citius Oncology include Immuneering (IMRX), Eledon Pharmaceuticals (ELDN), Alpha Teknova (TKNO), Niagen Bioscience (NAGE), and Surrozen (SRZN). These companies are all part of the "pharmaceutical products" industry.

How does Citius Oncology compare to Immuneering?

Citius Oncology (NASDAQ:CTOR) and Immuneering (NASDAQ:IMRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

Immuneering's return on equity of -31.93% beat Citius Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Oncology	N/A	-99.47%	-42.16%
Immuneering	N/A	-31.93%	-29.92%

70.5% of Citius Oncology shares are held by institutional investors. Comparatively, 67.7% of Immuneering shares are held by institutional investors. 9.8% of Citius Oncology shares are held by company insiders. Comparatively, 22.9% of Immuneering shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Citius Oncology has a beta of 3.42, indicating that its share price is 242% more volatile than the broader market. Comparatively, Immuneering has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market.

In the previous week, Immuneering had 5 more articles in the media than Citius Oncology. MarketBeat recorded 6 mentions for Immuneering and 1 mentions for Citius Oncology. Citius Oncology's average media sentiment score of 1.89 beat Immuneering's score of 0.86 indicating that Citius Oncology is being referred to more favorably in the media.

Company	Overall Sentiment
Citius Oncology	Very Positive
Immuneering	Positive

Citius Oncology presently has a consensus price target of $6.00, suggesting a potential upside of 803.61%. Immuneering has a consensus price target of $16.50, suggesting a potential upside of 293.79%. Given Citius Oncology's higher probable upside, research analysts plainly believe Citius Oncology is more favorable than Immuneering.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Immuneering	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Immuneering is trading at a lower price-to-earnings ratio than Citius Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Oncology	N/A	N/A	-$24.76M	-$0.47	N/A
Immuneering	N/A	N/A	-$56.03M	-$1.17	N/A

Summary

Citius Oncology and Immuneering tied by winning 7 of the 14 factors compared between the two stocks.

How does Citius Oncology compare to Eledon Pharmaceuticals?

Eledon Pharmaceuticals (NASDAQ:ELDN) and Citius Oncology (NASDAQ:CTOR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, valuation, earnings, dividends, analyst recommendations and risk.

Eledon Pharmaceuticals currently has a consensus target price of $9.67, suggesting a potential upside of 170.77%. Citius Oncology has a consensus target price of $6.00, suggesting a potential upside of 803.61%. Given Citius Oncology's higher possible upside, analysts clearly believe Citius Oncology is more favorable than Eledon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eledon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Citius Oncology's return on equity of -99.47% beat Eledon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eledon Pharmaceuticals	N/A	-116.97%	-41.91%
Citius Oncology	N/A	-99.47%	-42.16%

Eledon Pharmaceuticals has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market. Comparatively, Citius Oncology has a beta of 3.42, indicating that its stock price is 242% more volatile than the broader market.

Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Citius Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.77	N/A
Citius Oncology	N/A	N/A	-$24.76M	-$0.47	N/A

In the previous week, Eledon Pharmaceuticals had 2 more articles in the media than Citius Oncology. MarketBeat recorded 3 mentions for Eledon Pharmaceuticals and 1 mentions for Citius Oncology. Citius Oncology's average media sentiment score of 1.89 beat Eledon Pharmaceuticals' score of 0.84 indicating that Citius Oncology is being referred to more favorably in the news media.

Company	Overall Sentiment
Eledon Pharmaceuticals	Positive
Citius Oncology	Very Positive

56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. Comparatively, 70.5% of Citius Oncology shares are owned by institutional investors. 9.6% of Eledon Pharmaceuticals shares are owned by insiders. Comparatively, 9.8% of Citius Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Citius Oncology beats Eledon Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does Citius Oncology compare to Alpha Teknova?

Citius Oncology (NASDAQ:CTOR) and Alpha Teknova (NASDAQ:TKNO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk, media sentiment and analyst recommendations.

70.5% of Citius Oncology shares are owned by institutional investors. Comparatively, 13.8% of Alpha Teknova shares are owned by institutional investors. 9.8% of Citius Oncology shares are owned by company insiders. Comparatively, 12.5% of Alpha Teknova shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Citius Oncology has a net margin of 0.00% compared to Alpha Teknova's net margin of -41.07%. Alpha Teknova's return on equity of -24.32% beat Citius Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Oncology	N/A	-99.47%	-42.16%
Alpha Teknova	-41.07%	-24.32%	-16.34%

Alpha Teknova has higher revenue and earnings than Citius Oncology. Alpha Teknova is trading at a lower price-to-earnings ratio than Citius Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Oncology	N/A	N/A	-$24.76M	-$0.47	N/A
Alpha Teknova	$40.52M	5.56	-$17.26M	-$0.32	N/A

Citius Oncology has a beta of 3.42, indicating that its share price is 242% more volatile than the broader market. Comparatively, Alpha Teknova has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market.

In the previous week, Citius Oncology and Citius Oncology both had 1 articles in the media. Citius Oncology's average media sentiment score of 1.89 equaled Alpha Teknova'saverage media sentiment score.

Company	Overall Sentiment
Citius Oncology	Very Positive
Alpha Teknova	Very Positive

Citius Oncology presently has a consensus price target of $6.00, suggesting a potential upside of 803.61%. Alpha Teknova has a consensus price target of $8.00, suggesting a potential upside of 90.48%. Given Citius Oncology's higher possible upside, analysts plainly believe Citius Oncology is more favorable than Alpha Teknova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Alpha Teknova	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Summary

Alpha Teknova beats Citius Oncology on 7 of the 13 factors compared between the two stocks.

How does Citius Oncology compare to Niagen Bioscience?

Citius Oncology (NASDAQ:CTOR) and Niagen Bioscience (NASDAQ:NAGE) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership.

Niagen Bioscience has a net margin of 14.29% compared to Citius Oncology's net margin of 0.00%. Niagen Bioscience's return on equity of 22.68% beat Citius Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Oncology	N/A	-99.47%	-42.16%
Niagen Bioscience	14.29%	22.68%	16.23%

Citius Oncology has a beta of 3.42, indicating that its stock price is 242% more volatile than the broader market. Comparatively, Niagen Bioscience has a beta of 2.08, indicating that its stock price is 108% more volatile than the broader market.

In the previous week, Niagen Bioscience had 1 more articles in the media than Citius Oncology. MarketBeat recorded 2 mentions for Niagen Bioscience and 1 mentions for Citius Oncology. Citius Oncology's average media sentiment score of 1.89 beat Niagen Bioscience's score of 0.93 indicating that Citius Oncology is being referred to more favorably in the media.

Company	Overall Sentiment
Citius Oncology	Very Positive
Niagen Bioscience	Positive

Citius Oncology currently has a consensus price target of $6.00, indicating a potential upside of 803.61%. Niagen Bioscience has a consensus price target of $10.50, indicating a potential upside of 204.35%. Given Citius Oncology's higher probable upside, equities research analysts clearly believe Citius Oncology is more favorable than Niagen Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Niagen Bioscience	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Niagen Bioscience has higher revenue and earnings than Citius Oncology. Citius Oncology is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Oncology	N/A	N/A	-$24.76M	-$0.47	N/A
Niagen Bioscience	$129.42M	2.12	$17.38M	$0.21	16.43

70.5% of Citius Oncology shares are owned by institutional investors. Comparatively, 15.4% of Niagen Bioscience shares are owned by institutional investors. 9.8% of Citius Oncology shares are owned by insiders. Comparatively, 10.0% of Niagen Bioscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Niagen Bioscience beats Citius Oncology on 10 of the 14 factors compared between the two stocks.

How does Citius Oncology compare to Surrozen?

Citius Oncology (NASDAQ:CTOR) and Surrozen (NASDAQ:SRZN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation.

In the previous week, Surrozen had 3 more articles in the media than Citius Oncology. MarketBeat recorded 4 mentions for Surrozen and 1 mentions for Citius Oncology. Citius Oncology's average media sentiment score of 1.89 beat Surrozen's score of 0.93 indicating that Citius Oncology is being referred to more favorably in the media.

Company	Overall Sentiment
Citius Oncology	Very Positive
Surrozen	Positive

70.5% of Citius Oncology shares are held by institutional investors. Comparatively, 66.6% of Surrozen shares are held by institutional investors. 9.8% of Citius Oncology shares are held by company insiders. Comparatively, 31.7% of Surrozen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Citius Oncology has a beta of 3.42, suggesting that its stock price is 242% more volatile than the broader market. Comparatively, Surrozen has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market.

Citius Oncology presently has a consensus price target of $6.00, indicating a potential upside of 803.61%. Surrozen has a consensus price target of $42.00, indicating a potential upside of 79.56%. Given Citius Oncology's higher probable upside, research analysts clearly believe Citius Oncology is more favorable than Surrozen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Surrozen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Citius Oncology has higher earnings, but lower revenue than Surrozen. Citius Oncology is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Oncology	N/A	N/A	-$24.76M	-$0.47	N/A
Surrozen	$7.49M	36.24	-$242.03M	-$37.59	N/A

Citius Oncology has a net margin of 0.00% compared to Surrozen's net margin of -4,810.50%. Citius Oncology's return on equity of -99.47% beat Surrozen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Oncology	N/A	-99.47%	-42.16%
Surrozen	-4,810.50%	-4,055.04%	-154.08%

Summary

Citius Oncology beats Surrozen on 9 of the 16 factors compared between the two stocks.

Get Citius Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CTOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CTOR vs. The Competition

Export

Metric	Citius Oncology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$61.74M	$3.39B	$6.52B	$12.05B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	-1.41	20.00	24.00	24.42
Price / Sales	N/A	306.76	515.84	118.72
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	1.23	8.32	10.60	6.82
Net Income	-$24.76M	$23.94M	$3.57B	$337.56M
7 Day Performance	-16.99%	1.84%	0.59%	1.16%
1 Month Performance	-31.07%	-0.04%	1.54%	3.16%
1 Year Performance	-54.83%	44.82%	25.41%	30.60%

Citius Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CTOR Citius Oncology	1.9857 of 5 stars	$0.66 flat	$6.00 +803.6%	-54.8%	$61.74M	N/A	N/A	N/A	Positive News
IMRX Immuneering	2.7144 of 5 stars	$4.28 -4.7%	$16.50 +285.5%	+120.5%	$290.81M	N/A	N/A	60	Analyst Downgrade
ELDN Eledon Pharmaceuticals	1.9026 of 5 stars	$3.53 -6.1%	$9.67 +173.8%	+24.4%	$290.23M	N/A	N/A	10
TKNO Alpha Teknova	2.5809 of 5 stars	$5.18 -3.5%	$8.00 +54.4%	-23.4%	$287.91M	$40.52M	N/A	240	Positive News Gap Down
NAGE Niagen Bioscience	4.3386 of 5 stars	$3.54 -1.9%	$14.67 +314.3%	-74.7%	$287.52M	$129.42M	16.86	120

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CTOR) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Citius Oncology (CTOR) Competitors

CTOR vs. IMRX, ELDN, TKNO, NAGE, and SRZN

How does Citius Oncology compare to Immuneering?

Summary

How does Citius Oncology compare to Eledon Pharmaceuticals?

Summary

How does Citius Oncology compare to Alpha Teknova?

Summary

How does Citius Oncology compare to Niagen Bioscience?

Summary

How does Citius Oncology compare to Surrozen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTOR vs. The Competition

Citius Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Citius Oncology (CTOR) Competitors

CTOR vs. IMRX, ELDN, TKNO, NAGE, and SRZN

How does Citius Oncology compare to Immuneering?

Is CTOR or IMRX more profitable?

Do institutionals and insiders hold more shares of CTOR or IMRX?

Which has more risk & volatility, CTOR or IMRX?

Does the media prefer CTOR or IMRX?

Do analysts rate CTOR or IMRX?

Which has higher valuation & earnings, CTOR or IMRX?

Summary

How does Citius Oncology compare to Eledon Pharmaceuticals?

Do analysts prefer ELDN or CTOR?

Is ELDN or CTOR more profitable?

Which has more volatility and risk, ELDN or CTOR?

Which has stronger earnings & valuation, ELDN or CTOR?

Does the media refer more to ELDN or CTOR?

Do institutionals & insiders hold more shares of ELDN or CTOR?

Summary

How does Citius Oncology compare to Alpha Teknova?

Do insiders & institutionals hold more shares of CTOR or TKNO?

Is CTOR or TKNO more profitable?

Which has better valuation & earnings, CTOR or TKNO?

Which has more risk & volatility, CTOR or TKNO?

Does the media refer more to CTOR or TKNO?

Do analysts prefer CTOR or TKNO?

Summary

How does Citius Oncology compare to Niagen Bioscience?

Is CTOR or NAGE more profitable?

Which has more risk & volatility, CTOR or NAGE?

Does the media prefer CTOR or NAGE?

Do analysts rate CTOR or NAGE?

Which has stronger earnings and valuation, CTOR or NAGE?

Do insiders & institutionals have more ownership in CTOR or NAGE?

Summary

How does Citius Oncology compare to Surrozen?

Does the media prefer CTOR or SRZN?

Do institutionals and insiders have more ownership in CTOR or SRZN?

Which has more risk and volatility, CTOR or SRZN?

Do analysts prefer CTOR or SRZN?

Which has higher valuation and earnings, CTOR or SRZN?

Is CTOR or SRZN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTOR vs. The Competition

Citius Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools